CINCINNATI, July 29, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its fiscal Third quarter 2025 financial results on Monday, August 11, 2025, after market close. Gregory Crawford, Chief Executive Officer, and Hardik Mehta, Chief Financial Officer, will host a conference call for the investment community on Tuesday, August 12, 2025, at 10:00 a.m. (ET).
The call-in numbers for participants are:
| Canada/US Toll Free: | 1 (833) 752 3722 |
| International: | 1 (647) 846 8549 |
A live webcast of the call will be accessible via the investor section of the Company’s website through the following link: www.quipthomemedical.com.
ABOUT QUIPT HOME MEDICAL
The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services, and making life easier for the patient.
For further information please visit our website at www.quipthomemedical.com, or contact:
Cole Stevens
VP of Corporate Development
Quipt Home Medical Corp.
859-300-6455
This email address is being protected from spambots. You need JavaScript enabled to view it.
Gregory Crawford
Chief Executive Officer
Quipt Home Medical Corp.
859-300-6455
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.04 |
| Daily Change: | 0.05 2.51 |
| Daily Volume: | 193,291 |
| Market Cap: | US$88.620M |
August 12, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
